一例小细胞肺癌患者化疗后骨髓抑制的预防用药分析

摘要

Objective To discuss the indication and timing of prophylactic drug use for a small cell lung canc-er patient with myelosuppression after chemotherapy. Methods Clinical pharmacist evaluated the risk of febrile neutro-penia in the patient and suggested the timing of rational prophylactic G-CSF use,ensuring the safety of treatment. Re-sults The patient was estimated to have the indications for prophylactic G-CSF,and the timing of rational prophylactic G-CSF use was 24 ~48 h after chemotherapy. Conclusion Clinical pharmacists participate in the treatment,provide pharmaceutical care for rational drug use,thus preventing the risk of furthur myelosuppression of the patient.%目的：探讨1例小细胞肺癌患者化疗后骨髓抑制预防用药的指征和使用时机。方法临床药师通过查阅指南和相关文献，充分评估该患者发生粒细胞缺乏伴发热的风险等级，为患者的预防性使用重组人粒细胞集落刺激因子( G-CSF)的时机向医师提出建议，确保患者预防性用药的合理性。结果临床药师判断该患者具有预防性使用G-CSF的指征，建议正确的使用时机应在化疗结束后24~48 h开始。结论临床药师向医师提出合理建议，并提供相应的药学监护，避免患者骨髓功能受到进一步抑制。